FDA and User Fees: Time to Give 100%?
This article was originally published in RPM Report
Executive Summary
The share of drug reviews funded by industry fees has climbed steadily over two decades, and is going to jump again once generic drug and biosimilar fees become reality. It may be time to move to an all user fee model for drug reviews.
You may also be interested in...
100% User Fees For US FDA? Trump Budget Revives Important Issue For Industry – But Not This Year
Trump Administration’s surprising call for increased user fees probably won’t have much impact on pending reauthorization process, but it does put on the table an important question for the biopharma industry to consider for the long term: should FDA be fully funded by user fees?
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.
Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire
Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.